Analysis of US Patent 5,756,451: Scope, Claims, and Patent Landscape
What Does US Patent 5,756,451 Cover?
US Patent 5,756,451, filed by Eli Lilly and Company, issued in 1998, protects a specific class of compounds designed as kinase inhibitors, primarily targeting the Src family kinases. The patent encompasses novel molecules, methods of making these compounds, and their therapeutic applications, particularly in oncology.
Patent Scope Overview
The patent claims a series of heteroaryl and heterocyclic compounds. It covers compounds with structures defined by specific chemical formulas (see Table 1), methods for synthesizing these molecules, and their use in inhibiting kinase activity.
Key structural elements include:
- Heterocyclic cores such as pyrazolopyrimidine.
- Substituents at particular positions to modify activity.
- Variations allowing for a broad scope of analogs.
Table 1: Representative Chemical Structure of Claimed Compounds
| Element |
Description |
| Core |
Pyrazolopyrimidine ring system |
| Variable R1 |
Hydrogen, alkyl, or aryl groups |
| Variable R2 |
Heteroaryl groups (e.g., pyridyl, thiazolyl) |
The claims extend to pharmaceutical compositions and methods for treating kinase-driven diseases, such as cancer, using these compounds.
What Are the Main Claims?
The patent features 16 claims, with the primary claim being:
Claim 1: A compound of formula I, wherein the variables are defined as specific heteroaryl groups, with options for substitutions, aimed at inhibiting Src family kinases.
Secondary claims specify:
- Pharmaceutical compositions containing the compounds.
- Methods of synthesizing specific molecules.
- Methods of treating cancer via kinase inhibition.
Claim Scope Analysis
- Chemical breadth: The claims cover numerous derivatives through variable substitutions, expanding potential coverage.
- Method coverage: Claims include methods of synthesis and therapy, not limited to specific compounds.
- Therapeutic application: Uses for diseases characterized by abnormal kinase activity (e.g., cancers) are protected.
Potential Limitations:
- The patent's scope is limited to kinase inhibition, specifically Src family kinases.
- The chemical scope relies heavily on the defined variable groups; unclaimed derivatives outside those ranges are not protected.
Patent Landscape and Competitive Context
Patent Family and Related Filings
- The patent has family members filed in multiple jurisdictions, including Europe and Japan, securing territorial rights.
- Similar patents filed by Eli Lilly cover related kinase inhibitors, with overlapping chemical classes and therapeutic claims.
Key Competitors and Related Patents
| Company |
Patent Number |
Focus |
Filing Date |
Status |
| Pfizer |
US Patent 6,197,887 |
Fused heterocyclic kinase inhibitors |
1998 |
Granted |
| AstraZeneca |
WO 2000/070463 |
N-heteroaryl derivatives for kinase inhibition |
2000 |
Published |
| Novartis |
WO 2010/063118 |
Pyrazole-based kinase inhibitors |
2010 |
Published |
The landscape has extensive filings in kinase inhibitor space, with many compounds targeting similar kinase families, creating a dense patent terrain.
Patent Expirations and Opportunities
- Usually, patents filed before 2000 have expiration dates around 2018-2020, considering 20-year patent terms.
- Remaining patent life for US Patent 5,756,451 is approximately until 2018-2020, after which generic competition could emerge.
Patent Challenges and Limitations
- Prior art exists on kinase inhibitors with similar structural scaffolds, potentially affecting patent enforceability.
- The broad claims might face challenges if prior art demonstrates overlapping structures or methods.
Recent Trends in the Kinase Patent Landscape
- Increased focus on subtype-selective kinase inhibitors.
- Development of allosteric inhibitors providing alternatives outside the scope of ATP-competitive compounds.
- Growth of combinatorial and biomarker-driven therapeutic claims.
Strategic Implications
- Given the patent's expiration window, competitors could file for new patents on enhanced derivatives or targeted indications.
- Orphan disease or rare cancer claims could extend the patent's effective commercial life.
- Patent obscuration: Broad claims suggest potential for patent thickets, making infringement litigation complex.
Summary
US Patent 5,756,451 covers heteroaryl compounds as Src kinase inhibitors, with claims extending to synthesis methods and therapeutic uses. Its scope broadly covers certain chemical classes, but overlapping prior art and patent expirations limit long-term exclusivity. The patent landscape in kinase inhibitors is highly active, with competitors filing similarly structured patents; strategic positioning involves leveraging remaining patent life or developing improved derivatives.
Key Takeaways
- The patent protects a specific heteroaryl kinase inhibitor class targeting Src kinases, relevant in oncology.
- Main claims focus on compounds, synthesis methods, and therapeutic indications.
- The patent has likely expired around 2018-2020, opening opportunities for generics or new IP.
- The kinase inhibitor patent landscape is crowded, with active development in selective and allosteric inhibitors.
- Enforceability may be challenged due to prior art and claim scope limitations.
FAQs
1. Are the compounds covered by US Patent 5,756,451 still protected?
Most likely expired by 2020, making the patent unavailable for new claims but providing a period of market exclusivity during its term.
2. Can new kinase inhibitors be patented following this patent?
Yes, by designing compounds outside the claimed chemical scope or targeting different kinase subtypes or mechanisms.
3. How does the patent landscape impact drug development in kinase inhibitors?
It creates barriers to entry with dense patent thickets; innovation requires designing around existing claims or licensing.
4. What therapeutic areas are most affected by these kinase inhibitors?
Primarily oncology, especially cancers with overactive Src family kinases, and potentially inflammatory diseases.
5. What strategies could patent applicants use to differentiate from this patent?
Develop allosteric or highly selective inhibitors, improve pharmacokinetics, or target novel kinase pathways.
References
- Eli Lilly and Company. (1998). US Patent 5,756,451.
- World Intellectual Property Organization. (2000). WO 2000/070463.
- Pfizer. (2003). US Patent 6,197,887.
- AstraZeneca. (2000). WO 2000/070463.
- Novartis. (2010). WO 2010/063118.
